Articles From: AMETEK Announces Two Acquisitions to Amica Mature Lifestyles Announces Fourth Quarter and Year End Results for Fiscal 2014 and Quarterly Dividend


-- AMPTEK, Inc. Broadens AMETEK's Materials Analysis Capabilities -- -- Luphos GmbH Adds Unique Technology to AMETEK's Metrology Platform --
Sign-up for AMETEK Announces Two Acquisitions investment picks
BERWYN, Pa.
Sign-up for AMETEK Completes Acquisition Of Zygo Corporation investment picks
BERWYN, Pa.
Sign-up for AMETEK Declares Quarterly Dividend Of Nine Cents Per Share investment picks
BERWYN, Pa.
Sign-up for AMETEK Names Robert J. Amodei Vice President, Audit Services investment picks
Presentation to be Webcast at 2:45 PM ET on Tuesday, September 23 BERWYN, Pa.
Sign-up for AMETEK to Present at the Citi 2014 Industrials Conference investment picks
Affiliated Managers Group, Inc. (NYSE: AMG), a global asset management company, today announced the completion of the acquisition of River Road Asset Management from Aviva Investors North America Holdings, Inc. (a subsidiary of Aviva plc). River Road, which is based in Louisville, Kentucky, offers industry-leading value-oriented equity strategies using a proven “absolute value” investment philosophy designed to provide sustainable, low-volatility returns over the long term.
Sign-up for AMG Completes Investment in River Road Asset Management investment picks
Affiliated Managers Group, Inc. (NYSE: AMG) today reported its financial and operating results for the second quarter and six months ended June 30, 2014.
Sign-up for AMG Reports Financial and Operating Results for the Second Quarter and First Half of 2014 investment picks
Affiliated Managers Group, Inc. (NYSE: AMG) will report financial and operating results for the second quarter ended June 30, 2014 on Tuesday, July 29, 2014.
Sign-up for AMG to Announce Second Quarter Results on July 29, 2014 investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen Announces 2014 Third Quarter Dividend investment picks
Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening Results to Form Basis of Regulatory Filings Beginning in 1H 2015 THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint investment picks
Analysis Shows Study Met Primary and All Secondary Endpoints AMG 416 is a Novel Calcimimetic Administered Intravenously THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis investment picks
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol investment picks
Second Phase 3 Registrational Study Meets Primary and All Secondary Endpoints AMG 416 is a Novel Calcimimetic Administered Intravenously THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Webcast of 2014 Second Quarter Financial Results investment picks
Lung-MAP Trial Will Test Five Investigational Approaches, Including Amgen's Rilotumumab, an Investigational Fully Human Monoclonal Antibody THOUSAND OAKS, Calif.
Sign-up for Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer investment picks
2014/8/13
Sign-up for Amgen recalls syringes of anemia drug Aranesp investment picks
Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif.
Sign-up for Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia investment picks
NEW YORK (MarketWatch) -- Amgen Inc. shares (AMGN) climbed 3.5% in premarket trade Monday, after the company said a late-stage trial of a treatment for patients with relapsed multiple myeloma had positive results.
Sign-up for Amgen reports positive trial of multiple myeloma treatment investment picks
2014/8/4
By Joshua Jamerson Amgen Inc. said its Kyprolis drug met its primary endpoint in an interim analysis, showing progression-free survival for patients treated with relapsed multiple myeloma.
Sign-up for Amgen reports successful late-stage trial of cancer treatment investment picks
Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif.
Sign-up for Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA investment picks
Represents First Marketing Authorization Application in the European Union for a PCSK9 Inhibitor THOUSAND OAKS, Calif.
Sign-up for Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines Agency investment picks
First Marketing Authorization Application for an Oncolytic Immunotherapy in the European Union THOUSAND OAKS, Calif.
Sign-up for Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen To Present At The Morgan Stanley Global Healthcare Conference investment picks
Second Quarter 2014 GAAP EPS Were $2.01 2014 Total Revenues and Adjusted EPS Guidance Increased to $19.5-$19.7 Billion and $8.20-$8.40, Respectively Reallocating Resources to Drive Growth THOUSAND OAKS, Calif.
Sign-up for Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 investment picks
GREENVILLE, S.C., Sept.
Sign-up for AMIC Chicago Implements eRAD PACS Cloud Solution investment picks
2014/8/18
Amica Mature Lifestyles Inc. (“Amica” or the “Company”) (TSX Symbol:ACC) is pleased to announce the Company’s operating and financial results for the fiscal year and fourth quarter ended May 31, 2014.
Sign-up for Amica Mature Lifestyles Announces Fourth Quarter and Year End Results for Fiscal 2014 and Quarterly Dividend investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: AMETEK Announces Two Acquisitions to Amica Mature Lifestyles Announces Fourth Quarter and Year End Results for Fiscal 2014 and Quarterly Dividend
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices